Effect of a 1-Year Nutritional Blend Supplementation on Plasma p-tau181 and GFAP Levels among Community-Dwelling Older Adults: A Secondary Analysis of the Nolan Trial

K.V. Giudici1, P. de Souto Barreto1,2, S. Guyonnet1,2, C. Cantet1,2, H. Zetterberg3,4,5,6,7,8, C. Boschat9, J. Hudry9, S. Andrieu9,10, J.A.J. Schmitt9,11,12, B. Vellas1,2, K. Blennow1,4, for the NOLAN/DSA group

1. Gerontopôle of Toulouse, Institute of Ageing, Toulouse University Hospital (CHU Toulouse), Toulouse, France; 2. CERPOP UMR1295, University of Toulouse III, Inserm, UPS, Toulouse, France; 3. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; 4. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; 5. Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom; 6. UK Dementia Research Institute at UCL, London, United Kingdom; 7. Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China; 8. Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; 9. Brain Health Department, Nestlé Institute of Health Sciences, Nestlé Research, Société des Produits Nestlé S.A., 1000 Lausanne, Switzerland; 10. Department of Epidemiology and Public Health, Toulouse University Hospital (CHU Toulouse), Toulouse, France; 11. Singapore Institute of Food and Biotechnology Innovation (SIFBI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore; 12. Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

Corresponding Author: Kelly Virecoulon Giudici, Gérontopôle of Toulouse, Institute of Aging, 37 Allée Jules Guesde 31000 Toulouse, France, E-mail: kellygiudici@gmail.com

Abstract
BACKGROUND: Observational studies and some randomized controlled trials have suggested that nutritional supplementation could be a possible intervention pathway to prevent cognitive decline and Alzheimer’s disease (AD). As measuring amyloid-β and tau pathophysiology by positron emission tomography (PET) or cerebrospinal fluid (CSF) analyses may be perceived as complex, plasma versions of such biomarkers have emerged as more accessible alternatives with comparable capacity of predicting cognitive impairment.

OBJECTIVES: This study aimed to evaluate the effect of a 1-year intervention with a nutritional blend on plasma p-tau181 and glial fibrillary acidic protein (GFAP) levels in community-dwelling older adults. Effects were further assessed in exploratory analyses within sub-cohorts stratified accordingly to p-tau status (with the third tertile considered as high: ≥15.1 pg/mL) and to apolipoprotein E (APOE) ε4 allele status.

METHODS: A total of 289 participants ≥70 years (56.4% female, mean age 78.1 years, SD=4.7) of the randomized, double-blind, multicenter, placebo-controlled Nolan trial had their plasma p-tau181 assessed, and daily took either a nutritional blend (composed of thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cobalamin, vitamin E, vitamin C, vitamin D, choline, selenium, citrulline, eicosapentaenoic acid – EPA, and docosahexaenoic acid – DHA) or placebo for 1 year.

RESULTS: After 1-year, both groups presented a significant increase in plasma p-tau181 and GFAP values, with no effect of the intervention (p-tau181 between-group difference: 0.27 pg/mL, 95% CI: -0.95, 1.48; p=0.665; GFAP between-group difference: -3.28 pg/mL, 95% CI: -17.25, 10.69; p=0.644). P-tau- and APOE ε4-stratified analyses provided similar findings.

CONCLUSIONS: In community-dwelling older adults, we observed an increase in plasma p-tau181 and GFAP levels that was not different between the supplementation groups after one year.

Key words: p-tau, cognitive decline, Alzheimer, nutrition, clinical trials.

Introduction

In a worldwide context of increasing life expectancy and Alzheimer’s disease (AD) burden, identifying lifestyle factors that promote brain health is of high relevancy, and may help preventing or postponing cognitive decline, and consequently increasing quality of life. Observational studies associating nutritional factors to better cognitive function have suggested that nutritional supplementation could be a possible intervention pathway to prevent cognitive decline and Alzheimer’s disease (AD) (1-7). While ambiguous results have been found in trials supplementing single nutrients (8), other studies evaluating the combination of several nutrients (9), other studies evaluating the combination of several nutrients have suggested that this might be a better strategy (9-13). The Nolan Study was then designed to test this novel approach, through offering a nutritional blend (NB) developed to serve as a source of multiple nutrients to community dwelling older adults, and previously tested on cats (12) and dogs (13). In spite of not being able to affect cognitive function, as measured by clinical tests (except for a positive effect on the Cognitive Function Instrument – CFI study partner score), the nutritional blend positively improved two biomarkers that are believed to underlie an attenuation in cognitive decline during aging (14-16): plasma homocysteine (Hcy) levels decreased and erythrocyte omega-3 index increased after the 1-year intervention (17).

AD is a serious neurological disorder characterized by the gradual accumulation of amyloid-β (Aβ) plaques in the brain, which promotes neuronal toxicity, tau phosphorylation and aggregation, and neuronal death (18, 19). As measuring Aβ and tau pathology in the brain by positron emission tomography (PET) is expensive and have limited availability, and cerebrospinal fluid (CSF) collection may be regarded as complex to...
perform, plasma versions of such biomarkers have emerged as alternatives with comparable capacity of predicting cognitive impairment (20-23). Plasma tau phosphorylated at threonine 181 (p-tau181) has been identified as a predictor of cognitive decline (24) and of tau accumulation in the brain (25), with high performance to identify AD, while levels are normal in other dementias (26, 27). High p-tau181 levels were also found in the very early stages of the disease, even preclinically (28), and correlated tightly with other p-tau variants, such as p-tau231 and p-tau217 (29). Glial fibrillary acidic protein (GFAP) is a cytoskeletal protein commonly expressed in astroglia, which has also been associated with cognitive decline, amyloidosis and AD (30-33). Thus, it is of great interest to investigate whether the supplementation with the nutritional blend would be able to promote changes on plasma p-tau181 and on GFAP levels. Moreover, considering the important impact of the apolipoprotein E (APOE) ε4 allele on AD risk (34), subgroup analyses according to APOE ε4 status would also bring additional elements to the field.

This study aimed to evaluate the effect of a 1-year intervention with a nutritional blend composed of several nutrients (thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cobalamin, vitamin E, vitamin C, vitamin D, choline, selenium, citrulline, eicosapentaenoic acid – EPA, and docosahexaenoic acid – DHA) on plasma p-tau181 and GFAP levels among community-dwelling older adults. Effects were further assessed in exploratory analyses within sub-cohorts stratified according to p-tau181 status (low vs. high) and to APOE ε4 status (carriers vs. non-carriers).

Materials and Methods

Study design and population

The Nolan Study is a double-blind, multicenter, randomized, placebo-controlled trial (RCT) conducted...
in 18 centers in France. Participants were community-
dwelling older adults, recruited from December 2016 to
January 2018. Follow-up ended in February 2019. Major
inclusion criteria comprised: being ≥70 years old; self-
reporting subjective memory complaints; and having a
study partner to participate as a source of information.
Major exclusion criteria were: taking vitamin-B
supplements in the past three months; taking ω-3 PUFA
supplements containing >200 mg of DHA/day over six
months before inclusion; basic activities of daily living
(ADL) score <4; Mini-Mental State Examination (MMSE)
score <24; confirmed diagnosis of dementia. Detailed
inclusion and exclusion criteria has been described
elsewhere (17). Treatment with anticoagulants or platelet
aggregation inhibitors were accepted, but carefully
monitored, considering that ω-3 PUFA can affect platelet
function.

Out of the 362 participants who joined the Nolan study,
57 dropped-out during follow-up (n=26 intervention,
n=31 control; mean drop-out rate = 15.7%), totaling 305
participants at the end of the trial (n=154 intervention,
n=151 control). From those, 289 had their plasma p-tau181
and GFAP measured, and were then included in this
study. However, six aberrant values for GFAP at the
12-month visit were considered as outliers, and were not
included in the analyses. A detailed description of the
sample formation is provided in Figure 1.

**Ethical disclosure**

The Nolan Study was registered at www.clinicaltrials.
gov (protocol NCT03080675) and approved by the
Advisory Committee for Protection of Persons South
West and Overseas II (CPP SOOM II) and by the French
Agency for the Safety of Medicines and Health Products
(ANSM). All participants signed an informed consent.

**Randomization and masking**

For the original main analysis of the Nolan Study,
participants were randomly assigned (1:1) to either the
intervention group (receiving the supplementation with
the NB) or the control group (receiving placebo). Details
are given in Supplementary materials.

**Intervention**

Participants allocated in the intervention group were
instructed to take a nutritional blend daily, for one year.
The blend was characterized by two soft gel capsules
(with 775mg filling each) and by one powdered sachet
of =15g, to be mixed in 120mL of cold water. In the
meanwhile, participants in the control group took placebo
equivalent volumes. Total composition of a daily dose of
the NB consisted of 50mg of thiamin, 15 mg of riboflavin,
25mg of niacin, 23mg of pantothenic acid, 18mg of
pyridoxine, 0.15mg of biotin, 0.4mg of folic acid, 0.5mg
of cobalamin, 82.6mg of vitamin E, 500mg of vitamin C,
15μg of VD, 85mg of choline, 80μg of selenium, 3g of
citrulline, 700mg of EPA and 770mg of DHA. Additional
information about capsules and powered drink
composition is presented in Supplementary materials.

In addition to a total of six in-person visits over the
follow-up (screening, practice, baseline, 1 month,
6 months and 12 months), phone calls were set up
between visits at 3-month intervals to follow-up product
compliance, adverse events and concomitant medication
intake. Although dietary restrictions have not been made,
participants were instructed not to take any additional
supplements containing B-vitamins, DHA and/or EPA.

**Outcomes: plasma p-tau181 and GFAP**

Plasma samples were collected at baseline, 6 months,
and 12 months of follow-up, but p-tau181 and GFAP
were assessed only at baseline and 12 months. Plasma
p-tau181 concentration was measured in the Clinical
Neurochemistry Laboratory, University of Gothenburg
(Mölndal, Sweden), using an in-house Simoa method
based on the AT270 (specific for the threonine-181
phosphorylation site) and Tau12 (N-terminal epitope
6-18 on human tau protein), as described previously in
detail (26). Plasma GFAP concentration was measured
using the commercially available GFAP Discovery assay
(Quanterix, Billerica, MA). All measurements were
performed on an HD-X Analyzer (Quanterix, Billerica,
MA) in one round of experiments with baseline and
follow-up samples from the same individual side-by-
side on the assay plates by board-certified laboratory
technicians who were blinded to clinical information.
Intra-assay coefficients of variation were below 10%.

To define subgroups of participants with normal
(lower) and high p-tau status, and in the absence of a
consensual range in literature to determine it, tertiles
were used, with participants in the first and second
tertiles considered as low (<15.1 pg/mL) and those in the
third tertile considered as high (≥15.1 pg/mL).

**APOE ε4 allele status and other study variables**

The effect of intervention on plasma p-tau181 was
also investigated in exploratory analysis according to
the APOE ε4 allele status (carrier vs. non-carrier). In
addition, differences in plasma p-tau181 at baseline were
investigated according to sex (female, male), age ranges
(70 to 74 years, 75 to 79 years, 80 to 84 years, ≥85 years),
education (≤7 years, 8 to 9 years, ≥10 years), body mass
index (BMI) (≤21 kg/m², 21 to 24.9 kg/m², 25 to 29.9 kg/
m², ≥30 kg/m²), Clinical Dementia Rating (CDR) score
(0, 0.5) and amyloid status assessed by positron emission
tomography (PET) (positive, negative).
Table 1. Baseline characteristics of participants of the Nolan Study with plasma p-tau181 assessment

<table>
<thead>
<tr>
<th></th>
<th>Total n = 289</th>
<th>Nutritional blend n = 144</th>
<th>Placebo n = 145</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female)</td>
<td>163 (56.4%)</td>
<td>83 (57.6%)</td>
<td>80 (55.2%)</td>
<td>0.673*</td>
</tr>
<tr>
<td>Age (years)</td>
<td>78.1 (4.7)</td>
<td>78.3 (4.8)</td>
<td>77.9 (4.7)</td>
<td>0.435*</td>
</tr>
<tr>
<td>Age ranges</td>
<td></td>
<td></td>
<td></td>
<td>0.769*</td>
</tr>
<tr>
<td>70 to 74 years</td>
<td>70 (24.2%)</td>
<td>32 (22.2%)</td>
<td>38 (26.2%)</td>
<td></td>
</tr>
<tr>
<td>75 to 79 years</td>
<td>111 (38.4%)</td>
<td>56 (38.9%)</td>
<td>55 (37.9%)</td>
<td></td>
</tr>
<tr>
<td>80 to 84 years</td>
<td>82 (28.4%)</td>
<td>41 (28.5%)</td>
<td>41 (28.3%)</td>
<td></td>
</tr>
<tr>
<td>≥85 years</td>
<td>26 (9.0%)</td>
<td>15 (10.4%)</td>
<td>11 (7.6%)</td>
<td></td>
</tr>
<tr>
<td>Education (n = 288)</td>
<td></td>
<td></td>
<td></td>
<td>0.831*</td>
</tr>
<tr>
<td>≤ 7 years</td>
<td>24 (8.3%)</td>
<td>13 (9.0%)</td>
<td>11 (7.6%)</td>
<td></td>
</tr>
<tr>
<td>8 to 9 years</td>
<td>45 (15.6%)</td>
<td>21 (14.6%)</td>
<td>24 (16.7%)</td>
<td></td>
</tr>
<tr>
<td>≥10 years</td>
<td>219 (76.0%)</td>
<td>110 (76.4%)</td>
<td>109 (75.7%)</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>26.2 (4.0)</td>
<td>26.2 (3.8)</td>
<td>26.3 (4.1)</td>
<td>0.909*</td>
</tr>
<tr>
<td>&lt;21 kg/m²</td>
<td>23 (8.0%)</td>
<td>8 (5.6%)</td>
<td>15 (10.3%)</td>
<td>0.346*</td>
</tr>
<tr>
<td>21 to 24.9 kg/m²</td>
<td>100 (34.6%)</td>
<td>55 (38.2%)</td>
<td>45 (31.0%)</td>
<td></td>
</tr>
<tr>
<td>25 to 29.9 kg/m²</td>
<td>115 (39.8%)</td>
<td>57 (39.6%)</td>
<td>58 (40.0%)</td>
<td></td>
</tr>
<tr>
<td>≥30 kg/m²</td>
<td>51 (17.6%)</td>
<td>24 (16.7%)</td>
<td>27 (18.6%)</td>
<td></td>
</tr>
<tr>
<td>APOE ε4 status (n = 275)</td>
<td></td>
<td></td>
<td></td>
<td>0.279*</td>
</tr>
<tr>
<td>ε4 carrier</td>
<td>68 (24.7%)</td>
<td>30 (21.9%)</td>
<td>38 (27.5%)</td>
<td></td>
</tr>
<tr>
<td>ε4 non-carrier</td>
<td>207 (75.3%)</td>
<td>107 (78.1%)</td>
<td>100 (72.5%)</td>
<td></td>
</tr>
<tr>
<td>Plasma p-tau181 (pg/mL)</td>
<td>13.7 (5.8)</td>
<td>14.1 (6.0)</td>
<td>13.3 (5.6)</td>
<td>0.262*</td>
</tr>
<tr>
<td>Plasma GFAP (pg/mL) (n = 283)</td>
<td>182.7 (79.0)</td>
<td>194.4 (87.6)</td>
<td>171.0 (67.7)</td>
<td>0.013*</td>
</tr>
</tbody>
</table>

APOE, apolipoprotein E gene; GFAP, glial fibrillary acidic protein; p-tau181, phosphorylated tau at threonine 181; SD, standard deviation; *Except where indicated other.

* Chi-Square test; ** Equal variance two sample t-test, *** Unequal variance two sample t-test.

**Statistical analysis**

Means (SD – standard deviation) and frequencies (percentages) were used to characterize the studied population. Baseline characteristics of participants according to allocation groups were compared by Chi-Square test or Student’s t-test. Differences in plasma p-tau181 according to participants’ characteristics were tested using ANOVA or Student’s T-test. Efficacy analyses were done using data of all randomly assigned participants with plasma p-tau181 and GFAP measurements who completed the 12-month follow-up. Linear regression models adjusted on baseline data were performed in order to determine the effect of intervention, compared to placebo, on plasma p-tau181 and GFAP levels, including all available data (baseline and 12 months). The following fixed effects were included in the model: baseline value, intervention group, time (continuous variable), and interaction between group and time. Similarly, exploratory analysis according to plasma p-tau181 status and to APOE ε4 allele status was performed. The Statistical Analysis Software (SAS) version 9.4 (Cary, NC, USA) was used, with statistical significance set as 5%.

**Results**

**Characterization of the sample**

Table 1 presents baseline characteristics of participants according to randomized groups. The study sample of 289 Nolan participants had mean age 78.1 years (SD=4.7) and was composed of 56.4% female (n=163). Plasma p-tau181 did not differ between treatment groups at baseline (intervention: 14.1 pg/mL, SD=6.0 vs. control: 13.3 pg/mL, SD=5.6, p=0.262), but baseline plasma GFAP was higher in the intervention group (intervention: 194.4 pg/mL, SD=87.6 vs. control: 171.0 pg/mL, SD=67.7, p=0.013).

Differences in plasma p-tau181 were observed according to age range, sex, APOE ε4 status, CDR score and the presence of amyloid plaques assessed by PET scan, with higher plasma p-tau181 values observed among subjects ≥85 years old (p=0.002), male (p=0.023), APOE ε4 carriers (p=0.002), with CDR score 0.5 (p=0.001) and amyloid-positive (p=0.046). No differences were observed according to education and BMI. For plasma GFAP, differences were observed according to age range, sex, BMI, and CDR score, with higher GFAP observed among subjects ≥85 years old (p=0.001), female (p=0.005), female (p=0.005),
with BMI <21 kg/m² (p<0.0001) and with CDR score 0.5 (p=0.023). No differences were observed according to education, APOE ε4 status and amyloid status (determined by PET) (Table 2). Participants of the present study did not differ in baseline characteristics from those participants of Nolan who were not included due to the absence of the investigated biomarkers (Table 3).

### Effect of intervention on plasma p-tau181 and GFAP

After 1 year, plasma p-tau181 significantly increased in both groups, with no differences between participants who received the nutritional blend or those who received placebo (between-group difference: 0.27 pg/mL, 95%CI: -0.95, 1.48; p=0.665). Similar findings were observed for plasma GFAP, increasing in both groups over time and with no effect of intervention (between-group difference: -3.28 pg/mL, 95%CI: -17.25, 10.69; p=0.644) (Table 4).

### Exploratory analysis according to APOE ε4 allele status

The allele APOE ε4 was identified among 24.7% of the sample (n=68), and did not differ between groups (intervention: 21.9% vs. control: 27.5%; p=0.279) (Table 1). Additional analyses according to APOE ε4 status mostly provided similar findings to the observed among the total studied population, with no differences in plasma p-tau181 and GFAP changes between groups (difference in between-group differences over time for APOE ε4 carriers vs. non-carriers: p-tau181: 2.28 pg/mL, 95%CI: -0.58, 5.13; p=0.118; GFAP: 3.16 pg/mL, 95%CI: -28.24, 34.56; p=0.843) (Table 5).
**Exploratory analysis according to plasma p-tau181 status**

Exploratory analyses according to plasma p-tau181 status also found no effect of intervention on plasma p-tau181 and GFAP over 1-year, independently of p-tau status as baseline (difference in between-group differences over time for high vs. low: p-tau181: 0.81 pg/mL, 95% CI: -1.74, 3.36; p=0.532; GFAP: -12.49 pg/mL, 95% CI: -41.69, 16.72; p = 0.401) (Table 6). Interestingly, significant 1-year increase in plasma p-tau181 was only observed among participants with high p-tau181 at baseline (Table 6).

**Discussion**

Our study found no effect of a 1-year supplementation with a nutritional blend on plasma p-tau181 and GFAP levels among community-dwelling older adults, with both plasma biomarkers significantly increasing in both groups at the end of follow-up. Analyses according to APOE ε4 status provided similar findings. Analyses stratifying subjects according to their p-tau181 status at baseline revealed that only those with high p-tau presented significant increase in plasma p-tau181 after 1-year.

It is well understood that nutrition is a key factor affecting aging (35-37) and the development of neurodegenerative diseases (38-40). However, the influence of dietary factors on tau accumulation has not been largely explored so far. There are studies with animals pointing towards the beneficial role of nutrient supplementation. For example, in a study with amyloid precursor protein (APP) and presenilin 1 (PS1) double-transgenic mice (a well-established AD mouse model), vitamin D supplementation for 20 weeks decreased the expression levels of cortical APP, tau and p-tau (41). In addition, a 9-month DHA supplementation in 3xTg-
Table 5. Mixed-effect linear regression analysis for change from baseline in plasma p-tau181 according to intervention groups and APOE ε4 status among non-demented, community-dwelling older adults

<table>
<thead>
<tr>
<th>Nutritional blend vs. placebo</th>
<th>Between-group difference over time (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOE ε4 non-carrier</td>
<td>APOE ε4 carrier</td>
<td>APOE ε4 non-carrier</td>
</tr>
<tr>
<td>Plasma p-tau181 (pg/mL) (n=275)</td>
<td>1.17 (0.17, 2.16); 0.021</td>
<td>3.54 (1.67, 5.42); 0.002</td>
</tr>
<tr>
<td>Plasma GFAP (pg/mL) (n=270)</td>
<td>13.92 (2.88, 24.96); 0.014</td>
<td>18.11 (2.30, 38.52); 0.082</td>
</tr>
</tbody>
</table>

GFAP, glial fibrillary acidic protein; p-tau181, phosphorylated tau at threonine 181; Estimated with the mean at baseline; Defined as least one ε4 allele.

Table 6. Mixed-effect linear regression analysis for change from baseline in plasma p-tau181 according to intervention groups and plasma p-tau181 status among non-demented, community-dwelling older adults

<table>
<thead>
<tr>
<th>Estimated mean within-group change from baseline (95% CI)</th>
<th>Between-group difference over time (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutritional blend vs. placebo</td>
<td>Between-group difference over time (95% CI)</td>
<td>P-value</td>
</tr>
<tr>
<td>Nutritional blend vs. placebo</td>
<td>Estimated with the mean at baseline; Defined as least one ε4 allele.</td>
<td></td>
</tr>
</tbody>
</table>

AD mice was shown to reduce intraneuronal tau accumulation (42). It should be noted, however, that these studies were performed in AD animal models, a different approach from our investigation (focused on prevention and on the potential action of supplementation prior to disease onset, which also might demand higher exposure time compared to treatment scenarios). In humans, RCT have provided mixed findings. A RCT offering a 4-week high saturated fatty acid/glycemic index diet or a low SFA/GI diet for cognitively normal adults and adults with mild cognitive impairment (MCI) found that diets significantly modified CSF amino acid levels, and reported that such changes in amino acids were associated with changes in CSF tau and p-tau181 (43). On the other hand, a RCT investigating the effects of a 6-month supplementation with 2.3g/day of PUFAs on CSF biomarkers among AD patients found no effect of treatment on p-tau or t-tau (44). Other RCTs found no benefits of supplementation of single or combined nutrients or bioactive compounds (omega-3 PUFA (45); vitamin E, vitamin C, α-lipoic acid and coenzyme Q (46); copper (47); resveratrol (48)) on CSF t-tau and/or p-tau.

Multiple potential biological mechanisms are believed to be involved in this relationship between nutrients and tau accumulation (49). Vitamin E has been reported to prevent Aβ-induced tau phosphorylation both in vitro and in APP/PS1 transgenic mice, by inhibiting p38MAPK phosphorylation (50). Intraperitoneal injections containing trans retinoic acid (a vitamin A metabolite) were shown to reduce tau hyperphosphorylation by decreasing the activity of cyclin-dependent kinase 5 (CDK5 – a kinase involved in the abnormal phosphorylation of tau), in a study with APP/PS1 mice (51). Moreover, it has been shown that vitamin D reduced Aβ (25-35)-induced tau hyperphosphorylation through interplaying with glial cell line-derived neurotrophic factor (GDNF) signaling in SH-SY5Y cells (52). In accordance, Wu et al. (53) have recently shown that the activation of vitamin D receptor (VDR) reduced tau phosphorylation by inhibiting the GSK3β phosphorylation (Tyr216) in APP/PS1 mice. All such findings highlight the importance of further exploring how nutrition may contribute to fight tauopathies.

The evaluation of plasma GFAP in the present study brings additional elements to our investigation. GFAP is recognized as a marker of astrocyte reactivity (also known as astrocytosis or astrogliosis), a pathological process that is commonly found surrounding Aβ plaques in the brain of patients with AD (54). These activated glial cells are believed to be a defensive mechanism to fight amyloidosis, but when persistent, are pro-inflammatory and contribute to the worsening of AD progression (54). Therefore, the increasing of GFAP over time is associated with unhealthy prognosis (30–33). Our 1-year supplementation with the nutritional blend, however, did not mitigate the increase in plasma GFAP over time. Investigations on the effects of nutrient supplementation on GFAP are still scarce in literature, but there is evidence linking vitamin D (55) and EPA (56) supplementation with inhibition of glial activation in rodents. Future studies on the topic are hence encouraged.

Known as a strong genetic risk factor for the development of AD (34), the presence of the allele ε4 in the APOE gene importantly affects several metabolic pathways, including impaired cerebral glucose metabolism, altered microglia function (promoting
increased tau pathology), decreased cerebral blood flow and impaired ability of astrocytes to synthesize and secrete cholesterol (57). For this reason, people carrying the APOE ε4 allele are believed to benefit from specific nutritional recommendations, as higher DHA, vitamin D and B-vitamins intake, no alcohol consumption (57), lower saturated fat intake and the adherence to the Mediterranean dietary pattern (58). However, additional research offering high-level evidence is still needed before the consensual establishment of adapted dietary recommendations for heterozygous and homozygous APOE ε4 carriers. Despite all the metabolic particularities triggered by the APOE ε4 allele, we found no differences from main findings when analyses were separately performed according to APOE ε4 status. Neither did Yassin et al. (59) when evaluating DHA supplementation on CSF tau and p-tau levels among individuals with probable AD.

Although the supplementation tested in the present trial was able to improve omega-3 index and to reduce plasma Hcy levels (17), its 1-year duration may have been insufficient to affect plasma p-tau181 and GFAP, as also the given doses of each nutrient or compound. The fact that participants of the study were generally healthy individuals may also have exacerbated this relatively short follow-up. To our knowledge, the present study is the first to test the effect of a multi-nutrient supplementation on plasma p-tau181 levels, a biomarker that reflects amyloid and tau protein deposition in the brain (25, 60, 61), and is advantageous compared to CSF and brain measurements due to its lower costs and complexity. The randomized, controlled design of the study stands as one of its strengths. On the other hand, the fact that other p-tau variants (as p-tau217 and p-tau231) may not have been assessed in our study may be noted as a limitation. As other limitations, we must consider the relatively short duration of intervention, and the missing data for some of the study variables, especially amyloid status assessed by PET scan. The choice of the threshold data of p-tau181 status for the exploratory analysis (based on tertiles, once there are no validated established cutoffs so far) should be also noted. Moreover, most participants of the Nolan Study presented high educational level, so to whom specific nutritional supplementation may be more effective. Together with other advances in the field targeting lifestyle approaches, this would enable not only setting nutritional strategies for optimizing brain health and preventing or slowing the development of neurodegenerative diseases, but also to reduce the need of drugs and expensive treatments.

Conclusions

In this study, we observed a 1-year increase in plasma p-tau181 and GFAP levels among community-dwelling older adults that was not different between subjects receiving supplementation with a nutritional blend composed of several vitamins and minerals or those receiving placebo. Considering the novelty of the hypothesis tested in the present study, additional RCT with longer follow-ups and including other p-tau and astrocytosis biomarkers are needed, and may contribute to a better understanding if (and how) nutritional supplementation may be able to protect brain health and cognitive function through impacting tau accumulation, amyloidosis and glial activation. Additional research would also shed light on the identification of subgroups to whom specific nutritional supplementation may be more effective. Funding statement: The global sponsor of the Nolan Study is Société des Produits Nestlé SA, Nestlé Research, Lausanne, Switzerland. The sponsor for France is the University Hospital Center of Toulouse. The study sponsor was involved in study center set-up and monitoring, preparation and distribution of BPB and placebo, data collection and monitoring working closely with the investigators. Initial training sessions and yearly investigator’s meetings were organized by both the University Hospital Center of Toulouse and Nestlé. The data sharing activity was supported by the Association Monégasque pour la Recherche sur la maladie d’Alzheimer (AMPA) and the INSERM-University of Toulouse III UMR 1097 research unit.

Funding statement: The global sponsor of the Nolan Study is Société des Produits Nestlé SA, Nestlé Research, Lausanne, Switzerland. The sponsor for France is the University Hospital Center of Toulouse. The study sponsor was involved in study center set-up and monitoring, preparation and distribution of BPB and placebo, data collection and monitoring working closely with the investigators. Initial training sessions and yearly investigator’s meetings were organized by both the University Hospital Center of Toulouse and Nestlé. The data sharing activity was supported by the Association Monégasque pour la Recherche sur la maladie d’Alzheimer (AMPA) and the INSERM-University of Toulouse III UMR 1097 research unit.
Conflicts of interest: CB, JH and JAJs work at the Société des Produits Nestlé SA, Nestlé Research, Lausanne, Switzerland. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDS, Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Oxo Pharma, Pharmatech, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards, and/or as a consultant for Abbvie, Alector, Alzinaova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoeuticals, Passage Bio, Pinteo Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellelectricum, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). BV has served as a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and/or SAB member for Roche, Lilly, Eisai, TauX, Cerecin with personal compensation. The current study was funded by Nestlé to the Toulouse University Hospital without personal compensation. Other authors declare no conflict of interest.

Authors’ contributions: SA, BV and JAJs conceived the Nolan Study and designed research; CC analyzed data; KV wrote the paper; KV and CC had primary responsibility for final content. KB and HZ developed the p-tau181 Simoa immunoassay and supervised analyses in the present study. RB managed data and interpreted the data and revised the draft critically for intellectual content. All authors read and approved the final manuscript.

Clinical Trial Registry number: NCT03080675 registered at www.clinicaltrials.gov

References


EFFECT OF A 1-YEAR NUTRITIONAL BLEND SUPPLEMENTATION ON PLASMA p-TAU181 AND GFAP LEVELS AMONG COMMUNITY-DWELLING OLDER ADULTS


